Tandem Diabetes Care Shares Gain on FDA Clearance for Tubeless Insulin Delivery System
By Elias Schisgall
Shares of Tandem Diabetes Care rose after the diabetes technology company said the Food and Drug Administration had cleared its tubeless Tandem Mobi automated insulin delivery system.
Shares rose 12% to $19.62 in Friday morning trading. Despite the intraday gains, the stock remains down 11% year to date.
The company said Tandem Mobi is now the only tubeless automated insulin delivery system with FDA clearance for up to seven days of wear. A tubed insulin infusion option had already received clearance.
A full commercial launch in the U.S. is planned for the first half of next year.
"This clearance of the Tandem Mobi tubeless cartridge and infusion set creates even more possibilities for people living with diabetes, expanding the number of ways to experience the proven benefits of our Control-IQ+ AID technology," Chief Executive Officer John Sheridan said.
Write to Elias Schisgall at elias.schisgall@wsj.com
(END) Dow Jones Newswires
November 13, 2026 11:36 ET (16:36 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Growth Stocks to Buy While They’re Still Undervalued
3 of the Best Core Stocks to Own
3 Great New ETFs From 2026
Retirees: 5 Reasons to Consider Index Funds and ETFs
United States